Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
CORV was delisted on the 26th of May, 2020.
36 hedge funds and large institutions have $40.9M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
20% more capital inflows, than outflows
Capital inflows: $3.31M | Capital outflows: $2.75M
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
1.18% less ownership
Funds ownership: 46.57% → 45.38% (-1.2%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $216K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$775K |
| 2 |
Royce & Associates
New York
|
+$758K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$446K |
| 4 |
CPA
Columbia Pacific Advisors
Seattle,
Washington
|
+$335K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.58M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$486K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$173K |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$121K |
| 5 |
Two Sigma Investments
New York
|
-$84K |
CORV Hedge Fund Activity: Q4 2018 in Review
36 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q4 2018, worth a combined $40.9M — down 37% from $65.3M a quarter earlier.
Fund positioning in CORV was balanced in Q4 2018: 6 funds opened new positions, 6 closed out, 11 added to existing stakes and 9 trimmed.
The largest buyer was Clough Capital Partners, adding an estimated $775K. The largest seller was Stonepine Capital Management, cutting an estimated $1.58M.
- 36 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $40.9M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q4 2018, down 37% quarter-over-quarter.
- 6 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q4 2018 and 6 closed out, a net change of 0 holders.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q4 2018 was Clough Capital Partners, an estimated $775K added.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q4 2018 was Stonepine Capital Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2018.